Practolol beta-blockers

Description Results NMA

all cause death 1.57 [0.60; 4.05]

all cause death 1.16 [0.47; 2.86]

all cause death ∞ [NaN; ∞]

all cause death 1.12 [0.62; 2.02]

all cause death 0.82 [0.26; 2.57]

Sudden death 0.57 [0.36; 0.91]

cardiac death 0.75 [0.57; 0.99]

all cause death 0.80 [0.62; 1.02]

reinfarction 0.77 [0.57; 1.04]

Practolol (initial dose intravenously) (n=46)

vs.

(n=48)

No

Sample size: 46/48

Primary endpoint:

FU duration: 7 months

Practolol (initial dose intravenously) then atenolol (n=25)

vs.

(n=29)

Single

Sample size: 25/29

Primary endpoint:

FU duration: 6 months

Practolol (initial dose intravenously) (n=26)

vs.

(n=26)

Unclear

Sample size: 26/26

Primary endpoint:

FU duration: 1 week

Practolol (n=76)

vs.

(n=67)

Unclear

Sample size: 76/67

Primary endpoint:

FU duration: Short term

Practolol (n=72)

vs.

(n=71)

Double

Sample size: 72/71

Primary endpoint:

FU duration: 1 year

Practolol 200mg twice daily (n=1533)

vs.

placebo (n=1520)

Double blind

Parallel groups

Sample size: 1533/1520

Primary endpoint: death, reinfarction

FU duration: 12 months, up to 24 months